Literature DB >> 12960807

Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation.

Robin Reid1, M V Chandu de Silva, Lindsay Paterson, Eleanor Ryan, Cyril Fisher.   

Abstract

Low-grade fibromyxoid sarcoma (LGFMS) is a rare metastasizing soft tissue tumor with deceptively bland histologic features. The hyalinizing spindle cell tumor with giant rosettes (HSCT) is thought to be a closely related tumor differing only by the presence of collagen rosettes. We report the occurrence of a common t(7;16)(q34;p11) translocation in 2 cases of HSCT and 2 cases of LGFMS, thereby providing the first cytogenetic proof that LGFMS and HSCT are variants of the same entity. The tumors occurred in the thighs of 2 females and in the buttock and supraclavicular fossa of 2 males. One HSCT had a spectrum of unusual histologic features, including the presence of plump epithelioid cells with abundant cytoplasm and strands and nests of clear epithelioid cells separated by eosinophilic hyalinized stroma. Two cases showed a hitherto unreported, focal staining with epithelial membrane antigen, thus adding to the immunohistochemical profile of these tumors. LGFMS and HSCT probably have a wider spectrum of morphologic features than previously thought, the awareness of which will help pathologists to avoid diagnostic pitfalls. Demonstration of the t(7;16)(q34;p11) translocation will help to diagnose difficult cases with unusual histologic features.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960807     DOI: 10.1097/00000478-200309000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  21 in total

Review 1.  Low-Grade Fibromyxoid Sarcoma of the Head and Neck: A Clinicopathologic Series and Review of the Literature.

Authors:  Morgan L Cowan; Lester D Thompson; Marino E Leon; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2015-08-15

Review 2.  Fibromyxoma of the small bowel: a review.

Authors:  Meenakshi Chaku; Ehab Elakkary; Fabiana El Sarraf; Thanh Phan
Journal:  Dig Dis Sci       Date:  2007-03-14       Impact factor: 3.199

3.  Sclerosing epithelioid fibrosarcoma of the oral cavity.

Authors:  Camille T Elkins; Paul E Wakely
Journal:  Head Neck Pathol       Date:  2011-06-21

4.  Low grade fibromyxoid sarcoma: a case report and review of the literature.

Authors:  Christina Arnaoutoglou; Marios G Lykissas; Ioannis D Gelalis; Anna Batistatou; Anna Goussia; Michalis Doukas; Theodoros A Xenakis
Journal:  J Orthop Surg Res       Date:  2010-07-29       Impact factor: 2.359

5.  Low-grade fibromyxoid sarcoma of the hand: a case report.

Authors:  Guy Rubin; Micha Rinott; Alejandro Wolovelsky; Irit Elmalach; Nimrod Rozen
Journal:  Hand (N Y)       Date:  2010-06-16

6.  A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: a pathologic and molecular study of 18 cases.

Authors:  Carlos Prieto-Granada; Lei Zhang; Hsiao-Wei Chen; Yun-Shao Sung; Narasimhan P Agaram; Achim A Jungbluth; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-09-18       Impact factor: 5.006

7.  Fibromyxoid sarcoma in a 4-year-old boy: case report and review of the literature.

Authors:  G Rando; V Buonuomo; C D'Urzo; F Vecchio; M Caldarelli; C Pintus
Journal:  Pediatr Surg Int       Date:  2005-03-04       Impact factor: 1.827

8.  Epithelioid fibrosarcoma of the ovary.

Authors:  Kazuo Watanabe; Toshimitsu Suzuki
Journal:  Virchows Arch       Date:  2004-08-19       Impact factor: 4.064

9.  Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms.

Authors:  Julia A Bridge
Journal:  J Orthop Sci       Date:  2008-06-06       Impact factor: 1.601

Review 10.  Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.

Authors:  Cyril Fisher
Journal:  Virchows Arch       Date:  2009-04-28       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.